Positions 51–62 of 62.
WWB survo — Medutest came back 99.2% against a claimed 98.5%. One vial, one service, one member paying, which is the only kind of result this board should treat as…
Trying to get a straight answer on this: why does nobody talk about survodutide. Went slowly because everything published describes a deliberate escalation. That is the…
reading MASH threads from 2024 and half of it aged badly. It is the sort of thing everyone half-believes and nobody writes down. Histological endpoints in this field…
Something I keep coming back to: glucagon is the most under-discussed thing on this board. Imaging-derived liver fat fraction is a surrogate. It correlates with…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsthe hepatic fat advice in here is 2 years out of date. Change my mind, genuinely — I have no stake in being right about this. The relevant figures are 2 years, and they…
small win: glucagon stopped being a problem at week 36. This is a description of what happened to me and not a plan for anybody else. The endpoint vocabulary, because…
someone explain survodutide to me like I have not read a paper in years. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers…
Slightly embarrassed to be asking this, but: why does nobody talk about biopsy. Bought small because the evidence base is early. That is the only defensible position I…
why does nobody talk about MASH, and I want the answer with the reasoning attached rather than just the conclusion. What this compound is actually being developed for,…
Result first, context after: 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part . Everything below is how it was ordered,…
anyone else notice glucagon kicking in around week 47. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a…
survodutide is doing more work than we give it credit for. I have gone back and forth on this for months. What this compound is actually being developed for, since the…
Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference